Survival results were combined for each pre-specified category of regimens using a random-effects model, and meta-regression models were used to adjust for heterogeneity in some known prognostic factors.
There were three categories of treatment regimens: (1) short course chemotherapy for smear-positive PTB and seriously ill smear-negative PTB and EPTB cases, (2) retreatment regimen, (3) short course chemotherapy for smear negative PTB and EPTB patients who were not seriously ill.
The factor of treatment regimen showed different patterns of association for different staging combinations; however, none of these were statistically significant because there too few cases in any one category of treatment regimen.
They showed much higher tumor growth inhibition capability resulting in lowest tumor weight for each category of treatment regimen, confirming that active targeting of the tumor in vivo has promising therapeutic potential.
The complexity of movement of large quantities of people in and out of regimen categories can be problematic during the period of transition, as the number of regimens used becomes more complicated with the evolution of the WHO guidelines.
Data are number of regimens (percentage of regimen category) unless otherwise indicated.
Members of the medical team agreed upon the categories of CRM and treatment regimens that did not compromise the safety and efficacy profiles of previous regimens.
In addition, there was no evidence that UGIC risk was heterogeneous across the categories of both types and regimens of BPs refilled anytime during the observational period, nor during current and past periods.
In the past 5 years, major randomised trials and meta-analyses have led to significant progress in our understanding of the efficacy of fluoroquinolone prophylaxis, and the categories of patients (and chemotherapy regimens) associated with the greatest risk of FN, and hence those most likely to benefit from prophylactic treatment.
In each category with more than five changes of regimen IR's and corresponding 95%CI and IRR's and corresponding 95%CI adjusted for the same confounders as mentioned above in the analyses of IRR.
